David Cotter, MD, PhD

As dermatology patients enter clinical visits with information from social media, online forums, and AI inquiries, clinicians are juggling new concerns.

This interview with David Cotter, MD, PhD, highlights recent findings and new data in the psoriasis treatment space highlighted at AAD 2026.

Final reflections from physicians Stein Gold, Soung, and Cotter, emphasizing multidisciplinary, patient-focused advances in psoriasis and PsA care.

Highlights from Fall Clinical 2025, including emerging IL-23 and real-world data shaping the next phase of psoriasis research.

Comparison of APEX findings to prior IL-23 trials such as KEEPSAKE-1 and their implications for clinical practice.

Summary of the phase 3b APEX study showing guselkumab’s efficacy and inhibition of structural joint damage.

The panel discusses the prevalence and risk factors for psoriasis progression to psoriatic arthritis.

Debate on whether early IL-23–targeted therapy like ICO could delay or prevent PsA onset.

Examination of unique challenges and the importance of early, effective therapy in younger patients.

Review of new week 52 results showing durable responses and strong efficacy in both adults and adolescents.

Discussion of nasopharyngitis and URTI as the most common AEs and how the safety profile compares to other oral agents.

Overview of the ADVANCE trials showing ICO’s superior efficacy to deucravacitinib and consistent safety across 24 weeks.

Jennifer Soung, MD, outlines ICO’s mechanism as an IL-23 receptor antagonist and its significance in oral systemic therapy.

The panel explores patient attitudes toward oral vs injectable treatments and practical limitations of current oral agents.

Review of the updated IPC framework defining topical failure, reducing “topical churn,” and guiding earlier systemic escalation.

The experts analyze new patient and clinician survey data, revealing gaps between treatment satisfaction and practice realities.

Discussion on how patient goals, treatment experiences, and preference for oral agents shape individualized therapy plans.

Dr. Stein Gold introduces the panel and outlines the discussion’s focus on emerging therapies and evolving clinical approaches in psoriasis and PsA management.

Linda Stein Gold, MD, introduces the panel and outlines the discussion’s focus on emerging therapies and evolving clinical approaches in psoriasis and PsA management.

Cotter highlights his DERM 2025 conference presentation on navigating the diagnosis of melanoma and gene expression profiling of skin cancer.

This interview with Cotter highlights his session on the use of AI tools in the dermatology field.

Check out insights from SDPA 2025 on eczema, alopecia, vitiligo, burnout, and JAK inhibitor workups—key tips to improve dermatology care.

At SDPA 2025, Cotter highlights clinical patterns in alopecia areata that may respond better, or worse, to JAK inhibition and shares his approach to systemic therapy.